PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
7888254-4	1995	Tissue plasminogen activator was more potent than heparin in inhibiting superoxide production induced by opsonised zymosan or FMLP, but it did not affect the activity stimulated by PMA.	Superoxides	72-82	chromosome 20 open reading frame 181	Homo sapiens	0-28	
9179619-0	1997	Tissue plasminogen activator (tPA) inhibits human neutrophil superoxide anion production in vitro.	Superoxides	61-77	chromosome 20 open reading frame 181	Homo sapiens	0-28	
9179619-0	1997	Tissue plasminogen activator (tPA) inhibits human neutrophil superoxide anion production in vitro.	Superoxides	61-77	chromosome 20 open reading frame 181	Homo sapiens	30-33	
9179619-1	1997	Because neutrophils contribute to reperfusion injury associated with acute myocardial infarction (MI), and because tissue plasminogen activator (tPA) is often used in the management of MI, we evaluated the effect of tPA on superoxide (O2.-) production by human neutrophils in vitro.	Superoxides	223-233	chromosome 20 open reading frame 181	Homo sapiens	216-219	
9179619-2	1997	We found that adding increasing amounts of tPA significantly (r = 0.89, P < 0.025) and progressively reduced O2.- generation by neutrophils treated with phorbol myristate acetate (PMA) in vitro.	Superoxides	112-114	chromosome 20 open reading frame 181	Homo sapiens	43-46	
7888254-6	1995	When heparin was used in combination with tissue plasminogen activator, streptokinase, or urokinase at their therapeutic concentrations there was a significant inhibition of superoxide generation (70%, 30%, and 25%, respectively).	Superoxides	174-184	chromosome 20 open reading frame 181	Homo sapiens	42-70	
7888254-7	1995	The therapeutic concentrations of tissue plasminogen activator alone caused a reduction of 40% of neutrophil superoxide production.	Superoxides	109-119	chromosome 20 open reading frame 181	Homo sapiens	34-62